Mode
Text Size
Log in / Sign up
Phase 4 N=159 Randomized Double-blind Treatment

3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty

Osteoarthritis, Hip

Enrolled (actual)
159
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Percentage Ambulating Early After Spinal Anesthesia — 9; 20; 35 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
isobaric bupivacaine (Drug); hyperbaric bupivacaine (Drug); isobaric mepivacaine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Thomas Jefferson University
Primary completion
Nov 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage Ambulating Early After Spinal Anesthesia
9; 20; 35
SECONDARY
Return of Motor Function of the Thigh and Lower Leg
148; 123; 109
SECONDARY
Number of Patients With Dizziness Events
11; 7; 9
SECONDARY
Number of Patients With Urinary Retention Events
6; 8; 5
SECONDARY
Number of Patients With Transient Neurological Symptoms (TNS)
2; 6; 5
SECONDARY
Hospital Stay
26; 26; 22

Summary

Spinal anesthesia is commonly utilized for hip replacement surgery. Different medications used for spinal anesthesia work for different lengths of time. This study will compare three different spinal anesthesia medications in patients having hip replacement surgery to see if patients are able to get out of bed and walk earlier after surgery with one medication versus the others.

Eligibility Criteria

Inclusion Criteria

  • undergoing elective primary hip replacement surgery
  • American Society of Anesthesiologists physical status 1-3

Exclusion Criteria

  • hip fracture
  • contraindication to spinal anesthesia (refusal, coagulopathy or recent use of anticoagulant medication that prevents spinal anesthesia, local or systemic infection)
  • any other reason deemed significant by attending anesthesiologist
  • any patient requiring a wheelchair for ambulation or who cannot walk 25 feet with or without an assist device at time of surgery
  • presence of neuropathy in posterior thighs or buttocks
  • use of greater than the equivalent of morphine 25 mg IV (oxycodone 30 mg PO) daily
  • any patient deemed a poor candidate for spinal anesthesia as determined by the attending anesthesiologist
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03948386). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search